Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics, a forward-thinking company specializing in cell therapies, recently made an exciting announcement. The company’s Board of Directors has approved a stock repurchase program of up to $1 million of Eterna Therapeutics’ common stock. This decision reflects the board’s confidence in the company’s long-term plan and its dedication to enhancing the value for its shareholders.

The stock repurchase program allows Eterna Therapeutics to buy back its own stock through various methods like open market transactions or private negotiations. These repurchases will be carefully managed by the company’s leadership, considering factors such as market conditions and stock prices. Importantly, there is no set end date for this program, and it can be adjusted or stopped at any time without advance notice.

Sanjeev Luther, the President and CEO of Eterna Therapeutics, shared, “This buyback program underscores our belief in Eterna Therapeutics’ trajectory.” For more details, you can visit their website at https://www.eternatx.com/.

Eterna Therapeutics is a publicly traded company that focuses on developing cutting-edge, safe, and effective off-the-shelf cell therapies for advanced solid tumors. They are currently concentrating on innovative treatments for triple-negative breast cancer and platinum-resistant, TP53-mutant ovarian cancer. One of their lead products, ERNA-101, aims to deliver pro-inflammatory cytokines to the tumor microenvironment to enhance anti-tumor immunity.

In conclusion, Eterna Therapeutics’ stock repurchase program demonstrates their commitment to their future and the confidence they have in their strategic vision. Investors and those interested in the field of cell therapies can learn more about Eterna Therapeutics and their groundbreaking work on their website.